8-K filed Nov 9, 2026 at 06:30 ET
Abeona Therapeutics entered into a securities purchase agreement with institutional investors to sell up to 8,000,043 shares and/or pre-funded warrants at $3.75 per share, raising approximately $30M in gross proceeds. Simultaneously, the company completed an asset acquisition from Ellodi Pharmaceuticals for $20M in stock, funded by the PIPE. The combined transactions dilute existing shareholders by roughly 13-15% based on the $224M market cap, while the activist stake (6.1%) filed 17 days ago adds pressure for strategic change.